Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101. The $60 per share is a handsome, more than 100% premium on Pandion’s closing share… Read More »Merck takes on Lilly/Nektar in IL-2 with $1.85bn Pandion buy
New Models of Care in the Post-Covid Healthcare World Observations on models of care in a post-COVID world from HLTH VRTL 2020 with comments on applicability to autoimmune conditions. The Doctor Weighs In
Dealing with a Rare Eye Disease in the Midst of COVID19 After being diagnosed with a rare eye disease, a doctor learns the best treatment is immunosuppression-a risky choice in the midst of COVID19 The Doctor Weighs In
The drugmaker emphasized the full global rights it would acquire to Momenta’s lead asset, nipocalimab, which it is developing for several autoantibody-driven diseases and that in certain indications could have peak sales of more than $1 billion.
While there had been some risks to filgotinib’s approval cited before, analysts expressed surprise at the decision, with one writing it would likely delay approval by at least a year. Shares of both companies fell sharply on the news.
The agency approved Enspryng for the disease, which is often misdiagnosed as multiple sclerosis and can cause blindness, muscle weakness and paralysis.